<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595474</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000092</org_study_id>
    <nct_id>NCT04595474</nct_id>
  </id_info>
  <brief_title>Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes</brief_title>
  <official_title>Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Patients With Type 1 Diabetes Using Vibration-Controlled Transient Elastography and Noninvasive Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)&#xD;
      in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging&#xD;
      and serum-based methods with the goal of identifying high-risk patients with advanced&#xD;
      fibrosis who should be prioritized for specialty referral&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective cohort, single-center, single-arm study screening adult subjects with&#xD;
      type 1 diabetes from the Joslin Diabetes Center outpatient clinic mainly through physician&#xD;
      referrals for NAFLD and advanced fibrosis. Subjects will undergo a one-time screening which&#xD;
      will last for about 30 minutes.&#xD;
&#xD;
      The following procedures will be conducted during the study visit:&#xD;
&#xD;
        1. Blood draw for metabolic measurements (HbA1c, lipid panel, ALT, AST, serum albumin,&#xD;
           complete blood count-CBC)&#xD;
&#xD;
        2. FibroScan Measurements (LSM and CAP)&#xD;
&#xD;
        3. Anthropometric measurements (weight, height, BMI calculation, waist, and hip&#xD;
           circumference)&#xD;
&#xD;
        4. Systolic and diastolic blood pressure&#xD;
&#xD;
      Blood Draw:&#xD;
&#xD;
      Samples of blood taken during the trial for laboratory testing will include the following&#xD;
      metabolic measurements: AST, ALT, Platelets, percentage A1C, and lipid parameters (TC, LDL,&#xD;
      HDL, TG).&#xD;
&#xD;
      Fibroscan: Vibration controlled transient elastography (VCTE) or FibroScan® (EchoSens, Paris,&#xD;
      France) is a simple aid to diagnose adult patients with chronic liver diseases. FibroScan&#xD;
      provides a fast and reliable alternative to hepatic needle biopsy. In this 5-7 minute test,&#xD;
      the investigator induces a mild amplitude shear wave into liver tissue from a small&#xD;
      mechanical vibrator at the end of the FibroScan probe. VCTE evaluates a representative volume&#xD;
      of the liver that is 100-fold greater than needle biopsy and the liver stiffness measurement&#xD;
      (LSM) is expressed in kilopascals (kPa) with values &gt;9.8 kPa being consistent with the&#xD;
      presence of advanced fibrosis/cirrhosis. Typically, 10 successful VCTE measurements with a&#xD;
      median interquartile range/median ration of less than 30% are needed to have a reliable LSM.&#xD;
&#xD;
      FIB-4 Index: This is a noninvasive surrogate biomarker of advanced fibrosis that is&#xD;
      calculated using the following formula:&#xD;
&#xD;
      FIB-4 = Age (years)×AST (U/L)/[PLT(109/L)×√ALT(U/L)] (Sterling, Lissen et al. 2006)&#xD;
      FIB-4&gt;2.67 is consistent with the presence of advanced fibrosis with 80% PPV.&#xD;
&#xD;
      NAFLD Fibrosis Score (NFS): This is a noninvasive surrogate biomarker of advanced fibrosis&#xD;
      that is calculated using the following formula:&#xD;
&#xD;
      NFS= -1.675 + 0.037 - age (years) + 0.094 - BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no =&#xD;
      0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×109/l) - 0.66 × albumin (g/dl).&#xD;
&#xD;
      NFS&gt;0.676 is consistent with the presence of advanced fibrosis&#xD;
&#xD;
      Anthropometric measurements: These include weight, height, BMI calculation, waist, and hip&#xD;
      measurements. Measurements will be done using standardized anthropometric techniques.&#xD;
&#xD;
      Follow up may be required for High-risk patients with advanced fibrosis. If patient consents,&#xD;
      referring or treating physicians will be notified and provided with fibroscan results for&#xD;
      possible referral to hepatologists for further evaluation and intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with NAFLD</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>Controlled Attenuation Parameter (CAP) will be used to define the presence of NAFLD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with advanced fibrosis</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>Transient elastography will be used to define the presence of fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with advanced fibrosis per NAFLD fibrosis score-NFS</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>NFS will be calculated using the following formula:&#xD;
NFS= -1.675 + 0.037 - age (years) + 0.094 - BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×109/l) - 0.66 × albumin (g/dl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with advanced fibrosis per Fibrosis-4 (FIB-4) index</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>FIB-4 will be calculated using the following formula:&#xD;
FIB-4 = Age (years)×AST (U/L)/[PLT(109/L)×√ALT(U/L)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>Association with level of diabetes control as reflected in percentage HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometrics</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>Association with BMI and waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>Baseline (one time point evaluation)</time_frame>
    <description>Association with lipid parameters (LDL, HDL, TG)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">533</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Fibrosis, Liver</condition>
  <condition>Type 1 Diabetes</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Study Cohort</arm_group_label>
    <description>533 adult subjects with type 1 diabetes with no secondary causes of fatty liver</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transient Elastography</intervention_name>
    <description>Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis</description>
    <arm_group_label>Study Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include subjects with type 1 diabetes receiving care at Joslin Diabetes&#xD;
        Center. Addiotnal subjects from the broader Boston area may be recruited for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male or female&#xD;
&#xD;
          2. Subject age between 18-75 years old&#xD;
&#xD;
          3. Subject with an established diagnosis of T1D for at least three months prior to&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant or lactating&#xD;
&#xD;
          2. Subject has an active malignancy&#xD;
&#xD;
        4.Subject with secondary causes of fatty liver including history of any of the following:&#xD;
&#xD;
          -  Hepatitis B or C virus infection&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Lipodystrophy&#xD;
&#xD;
          -  Abetalipoproteinemia&#xD;
&#xD;
          -  Current or previous use of any of the following medication: amiodarone, tamoxifen,&#xD;
             methotrexate,corticosteroids (e.g. Prednisone), or Valproate&#xD;
&#xD;
          -  Male subject consuming &gt;30 g of alcohol per day or female subject consuming &gt;20 g of&#xD;
             alcohol perday&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Hamdy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah Gardner, BS</last_name>
    <phone>6173094426</phone>
    <email>hannah.gardner@joslin.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaheen Tomah, MD</last_name>
    <phone>6173094144</phone>
    <email>shaheen.tomah@joslin.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Osama Hamdy, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaheen Tomah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic fatty liver disease (NAFLD)</keyword>
  <keyword>Nonalcoholic steatohepatitis (NASH)</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Screening</keyword>
  <keyword>Advanced fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

